Regencell Bioscience RGC
$4.18 −$0.18 (-4.13%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $4.18 0.00%
Open$4.43
Prev close$4.36
Day range$4.12 – $4.43
Volume111.1K
Market cap$2.07B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q4, ended Dec 2017
Revenue$861.60M+6.0% YoY
Operating profit$90.70M-4.5% YoY
Net profit$28.90M-46.4% YoY
Diluted EPS$0.19-44.1% YoY
Free cash flow$79.40M-22.8% YoY
Operating cash flow$154.30M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin62.4%
Operating margin10.5%
Net margin3.4%
Return on equity-128.5%
Return on assets-114.2%
Return on invested capital-122.9%
Current ratio10.77
Liabilities / assets9.4%
Cash & investments$14.19M
Total debt$59,499.00
Net cash (debt)$14.13M
Income statement
| Line item | 2026 ANNUAL | 2025 ANNUAL | 2024 ANNUAL | 2023 ANNUAL | 2022 ANNUAL |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $11.72M | $3.77M | $4.74M | $6.27M | $7.62M |
| Selling and Admin Expenses | $10.42M | $2.82M | $3.67M | $4.69M | $5.11M |
| -Selling & Marketing Expense | $6,486.00 | $8,014.00 | $125,427.00 | $262,664.00 | $25,275.00 |
| -General & Admin Expense | $10.42M | $2.81M | $3.55M | $4.43M | $5.08M |
| Research & Development | $1.30M | $948,289.00 | $1.07M | $1.58M | $2.51M |
| Operating Profit | -$11.72M | -$3.77M | -$4.74M | -$6.27M | -$7.62M |
| Other Income (Expense) | $22,520.00 | $185,772.00 | $373,505.00 | $211,342.00 | $23,215.00 |
| Other Non-Operating Income (Expenses) | $22,520.00 | $185,772.00 | $373,505.00 | $211,342.00 | $23,215.00 |
| Pretax Profit | -$11.70M | -$3.58M | -$4.36M | -$6.06M | -$7.59M |
| Tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Profit | -$11.70M | -$3.58M | -$4.36M | -$6.06M | -$7.59M |
| Profit from Continuing Operations | -$11.70M | -$3.58M | -$4.36M | -$6.06M | -$7.59M |
| Minority Interests | $0.00 | $0.00 | -$61,384.00 | -$191,199.00 | -$148,612.00 |
| Net Income to Parent Company | -$11.70M | -$3.58M | -$4.30M | -$5.87M | -$7.45M |
| Net Income to Common Stockholders | -$11.70M | -$3.58M | -$4.30M | -$5.87M | -$7.45M |
| Basic EPS | -$0.02 | -$0.01 | -$0.01 | -$0.01 | -$0.02 |
| Diluted EPS | -$0.02 | -$0.01 | -$0.01 | -$0.01 | -$0.02 |
Balance sheet
| Line item | 2026 ANNUAL | 2026 Q4 | 2026 Q2 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $14.73M | $14.73M | $3.01M | $5.76M | $5.76M |
| Total Current Assets | $14.22M | $14.22M | $2.36M | $4.90M | $4.90M |
| Cash and Cash Equivalents & Short-Term Investments | $14.19M | $14.19M | – | $4.90M | $4.90M |
| -Cash and Cash Equivalents | $14.19M | $14.19M | – | $2.42M | $2.42M |
| -Short Term Investments | $0.00 | $0.00 | – | $2.48M | $2.48M |
| Receivables | $30,702.00 | $30,702.00 | – | $5,798.00 | $5,798.00 |
| -Other Receivables | $30,702.00 | $30,702.00 | – | $5,798.00 | $5,798.00 |
| Total Non-Current Assets | $506,402.00 | $506,402.00 | $656,170.00 | $852,769.00 | $852,769.00 |
| Net PPE | $430,732.00 | $430,732.00 | – | $759,819.00 | $759,819.00 |
| -Gross PPE | $1.37M | $1.37M | – | $1.62M | $1.62M |
| -Accumulated Depreciation | -$938,959.00 | -$938,959.00 | – | -$857,267.00 | -$857,267.00 |
| Non-Current Prepaid Assets | $75,670.00 | $75,670.00 | – | $92,950.00 | $92,950.00 |
| Total Liabilities | $1.38M | $1.38M | $1.79M | $895,308.00 | $895,308.00 |
| Total Current Liabilities | $1.32M | $1.32M | – | $663,673.00 | $663,673.00 |
| Payables | $10,787.00 | $10,787.00 | – | $2,539.00 | $2,539.00 |
| -Due to Related Parties Current | $10,787.00 | $10,787.00 | – | $2,539.00 | $2,539.00 |
| Current Accrued Expenses | $1.07M | $1.07M | – | $348,354.00 | $348,354.00 |
| Short-Term Debt and Capital Lease Obligation | $236,312.00 | $236,312.00 | – | $312,780.00 | $312,780.00 |
| -Current Capital Lease Obligation | $236,312.00 | $236,312.00 | – | $312,780.00 | $312,780.00 |
| Total Non-Current Liabilities | $59,499.00 | $59,499.00 | – | $231,635.00 | $231,635.00 |
| Long Term Debt and Capital Lease Obligation | $59,499.00 | $59,499.00 | – | $231,635.00 | $231,635.00 |
| -Long Term Capital Lease Obligation | $59,499.00 | $59,499.00 | – | $231,635.00 | $231,635.00 |
| Total Equity | $13.35M | $13.35M | $1.22M | $4.86M | $4.86M |
| Stockholders' Equity | $13.35M | $13.35M | $1.22M | $4.86M | $4.86M |
| Capital Stock | $4,959.00 | $4,959.00 | – | $4,945.00 | $4,945.00 |
| -Common Stock | $4,959.00 | $4,959.00 | – | $4,945.00 | $4,945.00 |
| Additional Paid-In Capital | $50.29M | $50.29M | – | $30.12M | $30.12M |
| Retained Earnings | -$36.90M | -$36.90M | – | -$25.20M | -$25.20M |
| Gains/Losses Not Affecting Retained Earnings | -$45,262.00 | -$45,262.00 | – | -$64,786.00 | -$64,786.00 |
| Minority Interests | $0.00 | $0.00 | – | $0.00 | $0.00 |
| Other Non-Current Assets | – | – | $656,170.00 | – | – |
Cash flow
| Line item | 2026 ANNUAL | 2025 ANNUAL | 2024 ANNUAL | 2023 ANNUAL | 2022 ANNUAL |
|---|---|---|---|---|---|
| Operating Cash Flow | -$7.70M | -$3.11M | -$4.00M | -$4.96M | -$5.27M |
| Net cash flow from continuing operations | -$7.70M | -$3.11M | -$4.00M | -$4.96M | -$5.27M |
| Net Income from Continuing Operations | -$11.70M | -$3.58M | -$4.36M | -$6.06M | -$7.59M |
| Depreciation & Depletion & Amortization | $404,543.00 | $392,743.00 | $745,588.00 | $769,687.00 | $604,397.00 |
| Other Non-Cash Items | -$22,520.00 | -$185,772.00 | -$248,000.00 | -$85,400.00 | -$10,733.00 |
| Change in Working Capital | $398,805.00 | $18,858.00 | -$585,365.00 | -$508,945.00 | -$1.02M |
| -Change in Prepaid Assets | -$11,242.00 | $151,714.00 | -$85,415.00 | -$23,147.00 | -$104,625.00 |
| -Change in Payables and Accrued Expense | $733,490.00 | $217,122.00 | -$34,880.00 | $1,874.00 | -$489,025.00 |
| -Change in Other Current Liabilities | -$323,443.00 | -$349,978.00 | -$465,070.00 | -$487,672.00 | -$430,421.00 |
| Net cash flow from investing | $2.50M | $2.69M | $5.24M | $58,978.00 | -$10.78M |
| Net Cash Flow from Continuing Investing Activities | $2.50M | $2.69M | $5.24M | $58,978.00 | -$10.78M |
| Net PPE Purchase and Sale | $0.00 | -$152,689.00 | -$5,376.00 | -$26,422.00 | -$780,876.00 |
| Net Investment Purchase and Sale | $2.50M | $2.84M | $5.25M | $85,400.00 | -$10.00M |
| Financing Cash Flow | $16.95M | $0.00 | $102,282.00 | $134,913.00 | $22.41M |
| Net Cash Flow from Continuing Financing Activities | $16.95M | $0.00 | $102,282.00 | $134,913.00 | $22.41M |
| Net Common Stock Issuance | $18.62M | $0.00 | $0.00 | – | $22.67M |
| Proceeds from Stock Option Exercised | $102,561.00 | $0.00 | $0.00 | – | – |
| Net Other Financing Charges | -$1.78M | – | $102,282.00 | $134,913.00 | $164,000.00 |
| Ending Cash Balance | $14.19M | $2.42M | $2.96M | $1.56M | $6.42M |
| Net Change in Cash | $11.75M | -$427,360.00 | $1.34M | -$4.77M | $6.36M |
| Beginning Cash Balance | $2.42M | $2.96M | $1.56M | $6.42M | $59,413.00 |
| Effect of Exchange Rate Changes | $18,907.00 | -$114,760.00 | $53,221.00 | -$83,145.00 | $0.00 |
| Free Cash Flow | -$7.70M | -$3.27M | -$4.01M | -$4.99M | -$6.05M |
| Gain/Loss from Continuing Operations | – | – | – | $1,415.00 | – |
| Net Issuance Payments Of Debt | – | – | – | – | -$431,969.00 |
No comments yet — be the first to weigh in on RGC.
Sign in to join the discussion.